Company intelligence / Profile preview

Sonogenix

Boston, Massachusetts, United Statespmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Development stage: Preclinical

Overview

Preclinical results for the LOTUS device showed strong efficacy and safety in animal models. Approval was received to begin first-in-human studies targeting prevention of acute kidney injury due to contrast media. The company aimed to confirm increased renal function and decreased incidence of contrast-induced nephropathy in patients with chronic kidney disease, but no published clinical results are available[1].

Therapeutic areas: Nephrology
Modalities: DeviceNon-pharmacological therapy
Industry: Therapeutic Medical Devices

Beyond the preview

Go deeper on Sonogenix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sonogenix.

Explore the full profile